Insider Selling: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CFO Sells 4,000 Shares of Stock

Last updated on Wednesday, June 23, 2021 | 2021 MarketBeat

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CFO Bo Kruse sold 4,000 shares of the stock in a transaction that occurred on Tuesday, June 22nd. The stock was sold at an average price of $36.17, for a total value of $144,680.00. Following the completion of the transaction, the chief financial officer now owns 245,077 shares in the company, valued at approximately $8,864,435.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Bo Kruse also recently made the following trade(s):

  • On Friday, June 4th, Bo Kruse sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $33.48, for a total value of $133,920.00.
  • On Monday, May 24th, Bo Kruse sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $35.61, for a total value of $142,440.00.

YMAB traded up $0.17 during trading on Wednesday, hitting $34.17. 6,975 shares of the company traded hands, compared to its average volume of 297,633. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of -21.66 and a beta of 1.21. The firm's fifty day moving average price is $32.58. Y-mAbs Therapeutics, Inc. has a one year low of $24.77 and a one year high of $55.22.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Thursday, May 6th. The company reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.61 by $0.14. The firm had revenue of $5.38 million during the quarter, compared to analysts' expectations of $35.67 million. On average, sell-side analysts forecast that Y-mAbs Therapeutics, Inc. will post -1.06 EPS for the current year.

Several institutional investors have recently made changes to their positions in the company. Penserra Capital Management LLC raised its stake in Y-mAbs Therapeutics by 171.9% in the fourth quarter. Penserra Capital Management LLC now owns 930 shares of the company's stock valued at $46,000 after purchasing an additional 588 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in Y-mAbs Therapeutics in the first quarter valued at approximately $46,000. Pacer Advisors Inc. raised its stake in Y-mAbs Therapeutics by 137.2% in the first quarter. Pacer Advisors Inc. now owns 1,812 shares of the company's stock valued at $55,000 after purchasing an additional 1,048 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in Y-mAbs Therapeutics in the first quarter valued at approximately $89,000. Finally, E Fund Management Co. Ltd. bought a new position in Y-mAbs Therapeutics during the first quarter valued at approximately $97,000. 60.76% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts recently issued reports on the company. JPMorgan Chase & Co. reaffirmed an "overweight" rating and set a $52.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, March 22nd. HC Wainwright lifted their price objective on shares of Y-mAbs Therapeutics from $65.00 to $70.00 and gave the stock a "buy" rating in a report on Monday, March 1st. Bank of America upgraded shares of Y-mAbs Therapeutics from a "neutral" rating to a "buy" rating in a research note on Friday, May 7th. Wedbush reduced their target price on shares of Y-mAbs Therapeutics from $67.00 to $52.00 and set an "outperform" rating for the company in a research note on Wednesday, April 21st. Finally, Zacks Investment Research lowered shares of Y-mAbs Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, February 24th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. The company currently has an average rating of "Buy" and a consensus price target of $54.38.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.

See Also: What is the strike price in options trading?

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: Average Daily Trade Volume Explained


7 Precious Metals Stocks That Will Keep Your Portfolio On Trend

The growing acceptance of cryptocurrency is beginning to make mainstream investors rethink their idea of “store of value.” The trendy possibilities of Bitcoin, Ethereum, and any of the dozens of altcoins that exist on the blockchain are trending like the latest fashion.

However, the thing about fashion is that the more things change the more things stay the same. Just like the simple black dress that won’t go out of fashion, the same can be said for precious metals stocks. One way to think about it would be to say that the existence of a growing cryptocurrency market doesn’t change the value of precious metals.

Precious metals have long been known to be a safe-haven asset in times of market volatility and economic crisis. In fact, during the Covid-19 pandemic, gold prices surged about 30% breaking the $2,000 mark for the first time in its history. This was at a time when the prices of many cryptocurrencies were falling.

And precious metals have also been seen as a hedge against inflation, which seems like more of a certainty with the Federal Reserve’s pledge to keep interest rates at historically low rates into 2023.

Whether you’re looking to take your first steps at crafting a precious metals portfolio or if you want to fine-tune the one you have, we believe this special presentation is a good place to start your research. We’ve identified seven precious metals stocks that look to retain their allure in 2021.

View the "7 Precious Metals Stocks That Will Keep Your Portfolio On Trend".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.